Navigation Links
Celator(R) Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
Date:3/26/2009

PRINCETON, N.J., March 26 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, has accepted an invitation to present at the Future Leaders in the Biotech Industry conference in New York. Mr. Jackson will provide a corporate overview and an update on the company's progress with two ongoing Phase 2 clinical trials of CPX-351 in newly diagnosed acute myeloid leukemia (AML) patients and first-relapse AML patients. The presentation will take place on Thursday, April 2, 2009 at 4:00PM EDT in Room 411 of the Millennium Broadway Hotel & Conference Center.

Presenting companies are chosen by BioCentury based on rigorous selection criteria, including investor validation and upcoming milestones, informed by the collective intelligence of Thomson Reuters and the sponsors of the conference.

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved an
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
2. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
3. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
4. Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... The best way to cure most cases of cancer ... of this approach, however, is that the surgeon may ... local recurrence. , With a new technique, researchers at ... to help surgeons see the entire tumor in the ... approach relies on an injectable dye that accumulates in ...
(Date:7/29/2014)... Washington, DC (PRWEB) July 29, 2014 ... Accreditation, filmed during the 2014 Society for Cardiovascular Angiography ... will be released this week. The videos review the ... in accreditation services for the cardiac catheterization laboratory from ... , In the first video, Jane Kiah, MS, RN, ...
(Date:7/29/2014)... measuring "adaptive behavior" in boys with fragile X ... the largest longitudinal study of the inherited disorder ... a range of everyday social and practical skills, ... living such as getting dressed. In this study, ... with fragile X, in that it did not ...
(Date:7/29/2014)... The National Congress of American Indians (NCAI) and ... NFL team owner Dan Snyder asking him to disavow suggestions ... is emanating from “well-intentioned elites” who are “not Native Americans.” ... respond. , The Change the Mascot campaign today ... was first reported by Erik Brady of USA Today.* ...
(Date:7/29/2014)... Florida (PRWEB) July 29, 2014 Botanica Day ... having performed more than 12,000 Brazilian bikini waxes ... this milestone achievement, the spa has rolled out a number ... services. Those new to Botanica can now get a free ... , The iconic day spa located in downtown Clearwater, ...
Breaking Medicine News(10 mins):Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3Health News:Accreditation for Cardiovascular Excellence (ACE) Launches 3-Part Video Series: The Cost/Benefit of ACE Accreditation; ProMedica Toledo Hospital Achieves Accreditation 2Health News:Accreditation for Cardiovascular Excellence (ACE) Launches 3-Part Video Series: The Cost/Benefit of ACE Accreditation; ProMedica Toledo Hospital Achieves Accreditation 3Health News:Socialization relative strength in fragile X longitudinal study 2Health News:Native American Groups Urge Washington Team Owner Dan Snyder to Stop Claiming Name Change Issue Driven by "Elites" Who Are Not People of Color 2Health News:Award-Winning Botanica Day Spa Celebrates 12,000 Brazilian Bikini Waxes 2Health News:Award-Winning Botanica Day Spa Celebrates 12,000 Brazilian Bikini Waxes 3
... seeks insights into chronic, illnesses, including heart failure and COPD, ... ... VENTURA, Calif., Oct. 8 VivoMetrics announced today,that noted researcher Bruce D. ... VivoMetrics LifeShirt(R) System to,the South Pole to collect valuable data for his ...
... Oct. 8 NPS Pharmaceuticals,Inc. (Nasdaq: NPSP ... as,senior vice president and chief commercial officer, effective ... NPS executive team, Mr. O,Callaghan will be,responsible for ... activities, including the commercial development of NPS,s,late-stage products ...
... The Physicians Coalition,for Injectable Safety today issued ... lipolysis or other injectable treatments touted to,reduce localized ... not,be mistaken as an accepted medical or cosmetic ... fat, using compounded pharmaceuticals, or,herbal agents, claim a ...
... the stories of eight mothers who survived ... breast ... product and baby gear brand, celebrates the "Power of Pink" by,announcing the ... Month, the eight outstanding women will be recognized,during the Susan G. Komen ...
... NEW YORK, Oct. 8 Health Management Systems,Inc. ... business of Peer Review,Systems, Inc. d/b/a/ Permedion, an ... in Westerville, Ohio. With this,acquisition, HMS augments its ... offerings for state Medicaid agencies and,managed care organizations. ...
... likely than whites to get tamoxifen, for example , , MONDAY, ... that has spread to the lymph nodes are less likely ... chemotherapy than white women with the same level of disease ... to the lymph nodes, we are seeing that African-American women ...
Cached Medicine News:Health News:VivoMetrics' LifeShirt Going to South Pole to Uncover Clues to High-Altitude Illness 2Health News:VivoMetrics' LifeShirt Going to South Pole to Uncover Clues to High-Altitude Illness 3Health News:NPS Pharmaceuticals Names Brian O'Callaghan as New Chief Commercial Officer 2Health News:Consumer Safety Alert on Fat Dissolving Injections 2Health News:Consumer Safety Alert on Fat Dissolving Injections 3Health News:'Pink Power Moms' Unite in Atlanta for Day of Pampering and Recognition 2Health News:'Pink Power Moms' Unite in Atlanta for Day of Pampering and Recognition 3Health News:'Pink Power Moms' Unite in Atlanta for Day of Pampering and Recognition 4Health News:HMS Acquires Permedion to Expand Clinical Review Capabilities 2Health News:Black Women Get Less Breast Cancer Treatment 2Health News:Black Women Get Less Breast Cancer Treatment 3
(Date:7/29/2014)... Colo. , July 29, 2014 New ... (MARC) which could allow physicians to see and assess ... hold promise, according to study authors who released their ... 11 th Annual Meeting in Colorado ... to advance the field of neurointervention, a specialty that ...
(Date:7/29/2014)... , July 29, 2014 Numotion,s Board of ... Mike Swinford will be the company,s new Chief Executive ... successful 22-year career at GE where he worked primarily for ... annual revenue to over $5 billion. His most recent position ... "I am thrilled to join Numotion," said ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- MHG Medical ... has launched its Medical Equipment and X-ray ... services are tailored to the cruise industry,s unique ... industry operators to propose that they should develop ... new program is intended to create standardized processes ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3Numotion Names Mike Swinford CEO 2MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2
... OAKS, Calif. and INGELHEIM, Germany, Jan. 18, 2011 ... Ingelheim today announced they have signed an agreement under ... substantially all assets at Amgen,s Fremont California development and ... by the board of directors of each company and ...
... The U.S. Food and Drug Administration today approved Natroba ... lice infestation in patients ages 4 years and older. ... Head lice are parasitic insects found on people,s head, ... times a day but are not known to cause ...
Cached Medicine Technology:Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility 2Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility 3Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility 4Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility 5FDA Approves Head Lice Treatment for Children and Adults 2
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
Medicine Products: